Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1047 | Thyroid (non-cancer) | ECE2015

TPOAb as an autoimmune response or index of thyroid hypofunction in breast cancer?

Smyth Peter , McDermott E W M , O'Higgins N J

The observed association between thyroid disorders and breast cancer has provoked many investigations. One area where there is some, although far from universal, agreement is the finding of an increased prevalence of anti-thyroid autoantibodies in breast cancer patients compared to controls. Whether this is a feature of a generalised autoimmune response to breast cancer, or provoked by the enzyme thyroid peroxidase acting as an autoantigen, remains unclear. In this study we lo...

ea0036oc7.2 | Oral Communications 7 | BSPED2014

Urinary vitamin E metabolites as a biomarker of oxidative stress in type 1 diabetes

Bulwer Chloe , Mills Kevin , Sirka Ernestas , Hindmarsh Peter

Background: Oxidative stress has been implicated in the development and progression of complications in type 1 diabetes (T1DM). Vitamin E (α-tocopherol) undergoes β-oxidation of its chomanol ring and the resulting metabolite α-TLHQ has been proposed as a potential biomarker of oxidative stress. HbA1c relates in T1DM to microvascular complications predominantly although the end-points are late in disease development. The oxidative stress process may act independe...

ea0036P74 | (1) | BSPED2014

Impaired insulin and IGF2 signalling in the primordial growth disorder 3-M syndrome

Kallampallil Jins , Acimovic Ksenija , Hanson Daniel , Whatmore Andrew , Clayton Peter

Introduction: 3-M syndrome is associated with mutations in CUL7, OBSL1 and CCDC8 with the three proteins interacting within a novel growth pathway. The impact of this pathway on cellular growth has not been fully defined. We have shown that i) GH and IGF1 signalling are altered; ii) IGF2 expression is reduced and iii) expression of insulin receptor isoforms are altered in 3-M fibroblasts.Aim: To characterise the activa...

ea0035oc6.4 | Bone, calcium & vitamin D | ECE2014

The REPEAT Study: An open-label clinical trial evaluating the safety and efficacy of recombinant human parathyroid hormone, rhPTH(1–84), for the treatment of hypoparathyroidism in hungary

Lakatos Peter , Bajnok Laszlo , Lagast Hjalmar , Valkusz Zsuzsanna

In hypoparathyroidism, inadequate levels of parathyroid hormone (PTH) result in hypocalcemia and often hyperphosphatemia. Large doses of calcium (Ca) and active vitamin D are typically used to manage symptoms, although these are often associated with complications and do not address the underlying PTH deficiency. In the phase III REPLACE trial, 24 weeks of treatment with rhPTH(1–84) was associated with maintained serum Ca without urine Ca excretion increases despite clini...

ea0035p677 | Growth hormone IGF axis basic | ECE2014

Positive impact of GH treatment on trabecular bone using grey-level texture analysis

Kuzma Martin , Kuzmova Zuzana , Vanuga Peter , Killinger Zdenko , Payer Juraj

Introduction: GH deficiency (GHD) is associated with reduced bone mineral density (BMD) and treatment leads to its increase. BMD, a quantitative bone parameter, doesn’t bring whole information about bone status. Nowadays, bone quality shows as main determinant of bone strength, fracture prediction and treatment effect monitoring. A method to assess bone quality through the grey-level texture analysis from lumbar spine DXA scan is trabecular bone score (TBS).<p class="...

ea0058oc4.2 | Oral Communications 4 | BSPED2018

Gene expression signatures in children with growth hormone deficiency (GHD) and Turner syndrome (TS) predict response to growth hormone

Clayton Peter , Stevens Adam , Murray Philip , Garner Terence

Background: Recombinant human growth hormone (r-hGH) is the primary therapeutic agent for disorders of growth including growth hormone deficiency (GHD) and Turner syndrome (TS). There is a high cost associated with treatment and existing methods to predict response (and hence alter management) can only account for 40–60% of the variance.Methods: GHD (n=71) and TS patients (n=43) were recruited as part of a study (PREDICT) on the lo...

ea0034oc5.6 | Pituitary | SFEBES2014

A GH antagonist fusion with GH binding protein is biologically active, shows delayed clearance and inhibits growth in a rabbit model

Wilkinson Ian , Phipps Michael , Sayers Jon , Artymiuk Peter , Ross Richard

Background: Acromegaly is associated with increased morbidity and mortality, however currect medical treatment controls the disease in <60% of patients. Pegvisomant, a pegylated GH antagonist, controls the disease in over 95% of cases, but is not cost effective as it requires high dose daily injections and has side-effects. We have developed a technology for generating a long acting potent GH antagonist.Hypothesis: That a GH antagonist fused to GH bi...

ea0034p7 | Bone | SFEBES2014

Monitoring the bisphosphonate treatment holiday

Mumby Clare , Azmi Shazli , Selby Peter , Hayden Katharine , Adams Judith

There is concern about the effects of long-term bisphosphonate use. A ‘treatment holiday’ is now considered after 5 years but there is no evidence as to the best way in which to monitor this.Aim: To look at the effect that a ‘treatment holiday’ has on the bone turnover marker, amino-terminal propeptide (P1NP) and bone mineral density (BMD).Methods: A retrospective case note review of 55 patients currently underg...

ea0034p57 | Clinical practice/governance and case reports | SFEBES2014

Fixed dose radioactive iodine treatment for hyperthyroidism: experience of a district general hospital

Manjunatha Rashmi , Harris Katherine , Nawaz Sarfraz , Mahto Rajni , Horrocks Peter

Background: The short- and long-term clinical outcome of patients receiving radioactive iodine treatment (RAI) differs in various studies. There is little consensus regarding the most appropriate dose of RAI to be administered. The range of activities currently prescribed varies between 200 and 800 MBq, with majority of patients receiving 400–600 MBq. In our centre, all patients receive a standard fixed dose of 400 MBq.Aim: To assess the cure rate w...